Scientific Evidence
Evidence built from preclinical proof to human imaging and therapeutic development
This section summarizes the biological and translational evidence supporting Curasight’s development rationale.
Detailed human study results, patient datasets and publication-level findings are presented separately under Clinical Evidence.
Evidence progression
Target biology
Published literature links uPAR to invasion, metastasis and poor prognosis across multiple solid tumors.
Preclinical theranostics
AE105-based radioligands demonstrated target-specific imaging and therapeutic effects in animal tumor models.
First-in-human imaging
uPAR PET established clinical feasibility, biodistribution and target-specific tumor uptake.
Human translation
AE105-based uPAR PET studies established that uPAR can be visualized non-invasively in patients and provided the clinical foundation for target-accessibility, patient-selection and dosimetry hypotheses.
Explore the evidence
Clinical evidence
uPAR has moved from tissue biology to non-invasive imaging in patients.
Clinical evidence
A clinical program spanning imaging, prognosis, diagnosis and the first human delivery and dosimetry study supporting therapeutic development.
Clinical evidence
Peer-reviewed research supporting the uPAR platform.